Mike Hollan

Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.

Katsuyoshi Sugita, chief people officer and chief ethics and compliance officer at Astellas Pharma, discusses innovative methods that are improving DE&I in the industry.

Slack discusses the complications that patients have getting enrolled in clinical trials.

Wyatt discusses how these devices are changing patient monitoring in clinical trials.

The conversation took place during the Veeva R&D Summit in Boston.

Elizabeth Smalley, director of product management, data, and analytics at ArisGlobal speaks about her work at the software company in supporting the efforts of life sciences clinical and pharmacovigilance teams in signal detection.

Gill discusses her continuing work to transform clinical trials and improve the patient experience through DCTs.

Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.

Cleve talks about the future of the industry and how data remains a key focus.